Baxter reiterates FY26 financial outlook

Baxter International has reaffirmed its full-year 2026 financial outlook following strong second-quarter performance, with both earnings and revenue exceeding expectations. The company reported adjusted earnings per share (EPS) of $0.56 on revenue of $2.96 billion, surpassing analyst estimates of $0.37 per share and $2.80 billion in revenue, respectively. This outperformance was driven by growth across its Advanced Surgery, drug compounding, and Care & Connectivity Solutions segments.

The company raised its full-year guidance for organic sales growth to 2%–3% and adjusted EPS to $1.95–$2.15, up from the previous range of $1.85–$2.05. The updated outlook reflects improved execution, higher volumes, and cost structure actions, with management anticipating margin expansion in the second half of the year. Free cash flow also showed improvement, reaching $181 million in Q2, with year-to-date free cash flow totaling $257 million.

Despite these gains, Baxter faces ongoing challenges, including supply constraints in injectables and anesthesia, as well as margin pressures from higher manufacturing costs and lower gross and operating margins compared to the prior year. The company is also navigating field actions related to its Novum IQ LVP infusion system, which have impacted shipment and installation timelines.

Looking ahead, Baxter emphasized its focus on executing strategic priorities, including stabilizing core operations, strengthening the balance sheet, and driving continuous improvement through Baxter GPS. The company aims to achieve a net leverage ratio of approximately 3.0 times by year-end 2026 and remains committed to disciplined capital allocation.

Investor sentiment has responded positively, with shares rising 15.79% in premarket trading following the earnings release. However, analysts caution that while the near-term outlook is optimistic, the company must continue to address operational and margin challenges to sustain long-term growth.